STOCK MARKET BSE NSE

Cipla partners with Eli Lilly to market diabetes drug Basaglar in India

Cipla's tie up is with Eli Lilly and Company (India) Pvt Ltd, a 100 per cent subsidiary of the US based firm, the two firms said in a joint statement.

Published: 08th June 2018 02:40 PM  |   Last Updated: 08th June 2018 02:40 PM   |  A+A-

An employee works at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. | Reuters

By PTI

NEW DELHI: Drug firm Cipla today said it has partnered with Eli Lilly to market and distribute Lilly's insulin glargine injection, Basaglar, in India.

Cipla's tie up is with Eli Lilly and Company (India) Pvt Ltd, a 100 per cent subsidiary of the US based firm, the two firms said in a joint statement.

The companies did not disclose the financial details of the deal.

Cipla expects to start commercialising Basaglar in India by end of this year.

Cipla MD & Global CEO Umang Vohra said: "Diabetes continues to be a focus area for Cipla and with the launch of strong brand like Basaglar, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables.

" The company's focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication, he added.

Lilly India MD Luca Visini said: "This strategic partnership leverages Lilly's commitment to bring innovation to people suffering from diabetes in India and Cipla's strong on-ground footprint across the country.

" Cipla stock was trading 2.22 per cent up at Rs 552.25 on BSE.

More from Business.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp